G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2)

Nemoto,Kaoru

doi:10.3892/etm_00000101

G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2)

Authors:
- Kaoru Nemoto
View Affiliations

Affiliations: Department of Urology, Nippon Medical School, Chiba Hokusoh Hospital, Chiba 270-1694, Japan. k-n@nms.ac.jp
Published online on: July 1, 2010 https://doi.org/10.3892/etm_00000101
Pages: 647-650

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cdc25 phosphatases are dual-specific phosphatases that play a role in cell cycle progression. In many human cancers, Cdc25 phosphatases are overexpressed as compared with normal tissues. In addition, overexpression of Cdc25 phosphatases in prostate cancer is correlated with disease progression. The antiproliferative efficacy of Cdc25 phosphatase inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2) was investigated in the PC-3 asynchronous human prostate cancer cell line using a cell-based assay. The time course changes in cell cycle distribution and the modulation of cell cycle regulators after DA 3003-2 administration were analyzed using the MTT assay. We found that the relative IC50 of DA 3003-2 was 2-fold lower as compared with its congener (2-mercaptoethanol)-3-methyl-1, 4-naphthoquinone (NSC 672121). Asynchronous PC-3 cells accumulated in the G2/M phase at 24 h after treatment with 10 µM DA 3003-2 or 20 µM NSC 672121, which represent IC70 concentrations. Treatment of cells with DA 3003-2 caused hyperphosphorylation of Cdc2 tyr15 in cyclin B1 and cyclin A complexes. DA 3003-2 did not downregulate the protein expression levels of Cdc25s, cyclins and cyclin-dependent kinases (Cdks). To conclude, after DA 3003-2 administration asynchronous PC-3 cells accumulated in the G2/M phase, with hyperphosphorylation of the G2/M cyclin-Cdk complex.

View Figures

View References

1.	Kristjánsdóttir K and Rudolph J: Cdc25 phosphatases and cancer. Chem Biol. 11:1043–1045. 2004.
2.	Boutros R, Lobjois V and Ducommun B: CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 7:495–507. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Chiu YT, Han HY, Leung SC, Yuen HF, Chau CW, Guo Z, Qiu Y, Chan KW, Wang X, Wong YC and Ling MT: CDC25A functions as a novel AR corepressor in prostate cancer cells. J Mol Biol. 385:446–456. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ and Tsai SY: Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene. 22:734–739. 2003. View Article : Google Scholar : PubMed/NCBI
5.	Ozen M and Ittmann M: Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res. 11:4701–4706. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Lazo JS, Aslan DC, Southwick EC, Cooley KA, Ducruet AP, Joo B, Vogt A and Wipf P: Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem. 44:4042–4049. 2001. View Article : Google Scholar : PubMed/NCBI
7.	Lazo JS, Nemoto K, Pestell KE, Cooley K, Southwick EC, Mitchell DA, Furey W, Gussio R, Zaharevitz DW, Joo B and Wipf P: Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol. 61:720–728. 2002. View Article : Google Scholar : PubMed/NCBI
8.	Lazo JS and Wipf P: Is Cdc25 a druggable target? Anticancer Agents Med Chem. 8:837–842. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Tamura K, Southwick EC, Kerns J, Rosi K, Carr BI, Wilcox C and Lazo JS: Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res. 60:1317–1325. 2000.PubMed/NCBI
10.	Pu L, Amoscato AA, Bier ME and Lazo JS: Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7 -[corrected] (2-morpholin-4-ylethylamino)-quinoline-5, 8-dione. J Biol Chem. 277:46877–46885. 2002.PubMed/NCBI
11.	Brisson M, Nguyen T, Vogt A, Yalowich J, Giorgianni A, Tobi D, Bahar I, Stephenson CR, Wipf P and Lazo JS: Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Mol Pharmacol. 66:824–833. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Chmelar R, Buchanan G, Need EF, Tilley W and Greenberg NM: Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer. 120:719–733. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Balk SP and Knudsen KE: AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 6:1–12. 2008.PubMed/NCBI
14.	Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ and Dutta A: Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res. 56:4159–4163. 1996.PubMed/NCBI
15.	Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP Jr, Muraca PJ and Ross JS: Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44 downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol. 16:1302–1309. 1998.PubMed/NCBI
16.	Maddison LA, Huss WJ, Barrios RM and Greenberg NM: Differential expression of cell cycle regulatory molecules and evidence for a ‘cyclin switch’ during progression of prostate cancer. Prostate. 58:335–344. 2004.